Skip to main content
Press release

Pharming announces the presentation of the results of the RUCONEST® Phase II study for prophylaxis of Hereditary Angioedema attacks

Today Pharming announced that the results of its “Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human C1 Inhibitor for Prophylaxis of Hereditary Angioedema Attacks”, were presented by Marco Cicardi, Professor of Internal Medicine University of Milan, Hospital L. Sacco Milan and co-prinicipal investigator for the study.

Read more


Cookies: This website uses cookies Check the cookies page for more information Accept Decline